22. Unlocking the Undruggable: Quantro Therapeutics’ Mission to Transform Cancer Treatment

For more than three decades, transcription factors have been the great white whale of oncology drug discovery; tantalising, genetically validated, mechanistically central, and yet stubbornly out of reach. They sit at the heart of cancer biology, driving the gene expression programmes that allow tumors to grow, adapt and resist treatment. And still, despite representing nearly 10% of the human proteome, they’ve remained largely untouched by modern medicine.

But that landscape is shifting. A new wave of biotech innovators is challenging long‑held assumptions about what is and isn’t druggable. Among them is Quantro Therapeutics, a Vienna-based company backed by Boehringer Ingelheim and Evotec, and armed with a platform that promises to rewrite the rules of transcription factor drug discovery. Its technology, QUANTROseq, doesn’t just measure gene expression, it captures transcriptional activity in real time, revealing whether a compound is truly hitting its target or simply creating noise.

In this episode, your host Jo Shorthouse sits down with Quantro CEO Dr Michael Bauer to unpack why transcription factors have been so elusive, why the industry can no longer afford to ignore them, and how Quantro’s approach could reshape oncology pipelines at a moment when pharma is grappling with declining R&D productivity, rising development costs, and the most significant patent cliff in its history. From the complexities of MYC to the strategic importance of big‑pharma partnerships, we explore what it really takes to drug the undruggable and why this frontier may hold the key to the next era of cancer innovation.

● Feedback

● Subscribe (Get notified when new episodes are available. NO marketing!)

● Disclaimer  

● LinkedIn